Abstract
Δ 9-tetrahydrocannabinol (Δ 9-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses of Δ 9- THC. Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal models and in healthy volunteers. Thus, this article provides a critical review of the research evaluating antipsychotic potential of this cannabinoid. CBD appears to have pharmacological profile similar to that of atypical antipsychotic drugs as seem using behavioral and neurochemical techniques in animal models. Additionally, CBD prevented human experimental psychosis and was effective in open case reports and clinical trials in patients with schizophrenia with a remarkable safety profile. Moreover, fMRI results strongly suggest that the antipsychotic effects of CBD in relation to the psychotomimetic effects of Δ 9-THC involve the striatum and temporal cortex that have been traditionally associated with psychosis. Although the mechanisms of the antipsychotic properties are still not fully understood, we propose a hypothesis that could have a heuristic value to inspire new studies. These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.
Keywords: Cannabidiol, CBD, cannabis, antipsychotic, psychosis
Current Pharmaceutical Design
Title:A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation
Volume: 18 Issue: 32
Author(s): Antonio Waldo Zuardi, Jose Alexandre S. Crippa, Jaime E.C. Hallak, Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Philip K. McGuire and Francisco Silveira Guimaraes
Affiliation:
Keywords: Cannabidiol, CBD, cannabis, antipsychotic, psychosis
Abstract: Δ 9-tetrahydrocannabinol (Δ 9-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses of Δ 9- THC. Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal models and in healthy volunteers. Thus, this article provides a critical review of the research evaluating antipsychotic potential of this cannabinoid. CBD appears to have pharmacological profile similar to that of atypical antipsychotic drugs as seem using behavioral and neurochemical techniques in animal models. Additionally, CBD prevented human experimental psychosis and was effective in open case reports and clinical trials in patients with schizophrenia with a remarkable safety profile. Moreover, fMRI results strongly suggest that the antipsychotic effects of CBD in relation to the psychotomimetic effects of Δ 9-THC involve the striatum and temporal cortex that have been traditionally associated with psychosis. Although the mechanisms of the antipsychotic properties are still not fully understood, we propose a hypothesis that could have a heuristic value to inspire new studies. These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.
Export Options
About this article
Cite this article as:
Waldo Zuardi Antonio, Alexandre S. Crippa Jose, E.C. Hallak Jaime, Bhattacharyya Sagnik, Atakan Zerrin, Martin-Santos Rocio, K. McGuire Philip and Silveira Guimaraes Francisco, A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884681
DOI https://dx.doi.org/10.2174/138161212802884681 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of S-equol and Soy Isoflavones on Heart and Brain
Current Cardiology Reviews Lifestyle and Genetic Contributions to Cognitive Decline and Hippocampal Structure and Function in Healthy Aging
Current Alzheimer Research Pathways of Acetylcholine Synthesis, Transport and Release as Targets for Treatment of Adult-Onset Cognitive Dysfunction
Current Medicinal Chemistry Therapeutic Agents for Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Conference Report:5<sup>th</sup> International Conference on Nanotek & Expo, Nov 16-18, 2015, San Antonio TX, USA
CNS & Neurological Disorders - Drug Targets Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews Vascular Risk Factors and Lesions of Vascular Nature in Magnetic Resonance as Predictors of Progression to Dementia in Patients with Mild Cognitive Impairment
Current Alzheimer Research Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets Neural and Behavioral Responses to Systemic Immunologic Stimuli: A Consideration of Bacterial T Cell Superantigens
Current Pharmaceutical Design Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges
Current Neuropharmacology Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Editorial (New Wave from Immunology, Endocrine & Metabolic Agents in Medicinal Chemistr )
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Grey Matter Atrophy in Mild Cognitive Impairment / Early Alzheimer Disease Associated with Delusions: A Voxel-Based Morphometry Study
Current Alzheimer Research The Role of Aβ Peptides in Alzheimers Disease
Protein & Peptide Letters Amino-Alkyl-Cyclohexanes as a Novel Class of Uncompetitive NMDA Receptor Antagonists
Current Pharmaceutical Design Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice
CNS & Neurological Disorders - Drug Targets Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?
Current Alzheimer Research Different Effect of Vitamin D<sub>2</sub> and Vitamin D<sub>3</sub> on Amyloid-β40 Aggregation In Vitro
Current Alzheimer Research